Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KQ-2003 in Relapsed/Refractory Multiple Myeloma
NCT06223646Phase 2Recruiting
- Sponsor
- Novatim Immune Therapeutics
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of KQ-2003 in multiple myeloma (MM), sponsored by Novatim Immune Therapeutics. Started Jan 2024; status: recruiting.
02
Drugs
KQ-2003
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06223646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223646.